Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287
Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.
A stock expert thinks Ascendis is still good but less exciting than before. When an expert gets less bullish, it may mean the company's growth story is slowing down or the stock is already priced fairly high.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.